Optimization of GPR40 Agonists for Type 2 Diabetes

[Image: see text] GPR40 (FFA1 and FFAR1) has gained significant interest as a target for the treatment of type 2 diabetes. TAK-875 (1), a GPR40 agonist, lowered hemoglobin A1c (HbA1c) and lowered both postprandial and fasting blood glucose levels in type 2 diabetic patients in phase II clinical tria...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Liu, Jiwen (Jim), Wang, Yingcai, Ma, Zhihua, Schmitt, Mike, Zhu, Liusheng, Brown, Sean P., Dransfield, Paul J., Sun, Ying, Sharma, Rajiv, Guo, Qi, Zhuang, Run, Zhang, Jane, Luo, Jian, Tonn, George R., Wong, Simon, Swaminath, Gayathri, Medina, Julio C., Lin, Daniel C.-H., Houze, Jonathan B.
Format: Artigo
Jezik:Inglês
Izdano: American Chemical Society 2014
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027784/
https://ncbi.nlm.nih.gov/pubmed/24900872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml400501x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items